Celgene partners on Phase 0 cancer drug studies; FDA lifts clinical hold on Xencor's bispecific
→ Celgene is tying up with Seattle-based Presage Biosciences to test its early-stage cancer drugs on patients in Phase 0 studies. In …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
